A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA’s Benefit-Risk Framework

被引：0
|
作者：
Jane Namangolwa Mutanga
Ujwani Nukala
Marisabel Rodriguez Messan
Osman N. Yogurtcu
Quinn McCormick
Zuben E. Sauna
Barbee I. Whitaker
Richard A. Forshee
Hong Yang
机构：
[1] US FDA,Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research
[2] US FDA,Office of Therapeutic Products, Center for Biologics Evaluation and Research
来源：
The AAPS Journal | / 25卷
关键词：
advisory committees; benefit-risk; biological products; risk management; US Food and Drug Administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 10 条
  • [1] A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA's Benefit-Risk Framework
    Mutanga, Jane Namangolwa
    Nukala, Ujwani
    Rodriguez Messan, Marisabel
    Yogurtcu, Osman N.
    McCormick, Quinn
    Sauna, Zuben E.
    Whitaker, Barbee I.
    Forshee, Richard A.
    Yang, Hong
    AAPS JOURNAL, 2023, 25 (01):
  • [2] FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals
    Lackey, Leila
    Thompson, Graham
    Eggers, Sara
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (01) : 170 - 179
  • [3] Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages
    Wen, Shihua
    He, Weili
    Evans, Scott R.
    Quartey, George
    Norton, Jonathan D.
    Chuang-Stein, Christy
    Jiang, Qi
    Ma, Haijun
    Bhattacharya, Mondira
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (04): : 409 - 416
  • [4] Assessing the Benefit-Risk for New Drugs Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
    Brass, Eric P.
    DIABETES CARE, 2013, 36 (07) : 1823 - 1826
  • [5] Regulation of biologic oncology products in the FDA's Center for Biologics Evaluation and Research
    Bross, Peter F.
    Fan, Chaohong
    George, Bindu
    Shannon, Kevin
    Joshi, Bharat H.
    Puri, Raj K.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 133 - 136
  • [6] Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA's Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio
    Sun, Stephen
    Heske, Suzanne
    Mercadel, Melanie
    Wimmer, Jean
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (01) : 129 - 137
  • [7] FDA’s Benefit–Risk Framework for Human Drugs and Biologics: Role in Benefit–Risk Assessment and Analysis of Use for Drug Approvals
    Leila Lackey
    Graham Thompson
    Sara Eggers
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 170 - 179
  • [8] Regulatory Administrative Databases in FDA's Center for Biologics Evaluation and Research: Convergence Toward a Unified Database
    Jeffrey K. Smith
    The AAPS Journal, 2013, 15 : 388 - 394
  • [9] Regulatory Administrative Databases in FDA's Center for Biologics Evaluation and Research: Convergence Toward a Unified Database
    Smith, Jeffrey K.
    AAPS JOURNAL, 2013, 15 (02): : 388 - 394
  • [10] A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States
    Wallace, Megan
    Rosenblum, Hannah G.
    Moulia, Danielle L.
    Broder, Karen R.
    Shimabukuro, Tom T.
    Taylor, Christopher A.
    Havers, Fiona P.
    Meyer, Sarah A.
    Dooling, Kathleen
    Oliver, Sara E.
    Hadler, Stephen C.
    Gargano, Julia W.
    VACCINE, 2023, 41 (44) : 6456 - 6467
1